Radiation Oncology

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Throughout 2026, CancerNetwork® and the journal ONCOLOGY® will be dedicated to sharing the most critical developments in the radiation oncology field.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Neoadjuvant immunotherapy plus chemotherapy did not definitively increase the risk of severe pneumonitis compared with adjuvant immunotherapy.

Investigators assessed recurrence rates between axillary lymph node dissection recipients after neoadjuvant chemotherapy vs nonrecipients.

Overall survival significantly improved with radiation plus cisplatin/paclitaxel in the phase 2 RTOG 9911 trial over a historical control cohort.

Stereotactic body radiotherapy alone may be feasible instead of immediate systemic therapy in select patients with oligometastatic cancer.

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Sunil Dutta, MD, discusses how whole-breast radiation or systemic therapy is responsible for controlling low-volume disease.

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Ron Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.

Establishing guideline harmonization and practice standardization may help promote the safe and consistent delivery of radiopharmaceutical therapies.

Due to certain errors in the 2026 PFS Final Rule pre-publication, ACRO has issued a statement while awaiting the publication of the 2026 HOPPS Final Rule.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Combinations of antiangiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.